Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Operations: 2013-2024

Historic Cash from Operations for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$232.3 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Operations fell 24.97% to -$84.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.0 million, marking a year-over-year decrease of 65.48%. This contributed to the annual value of -$232.3 million for FY2024, which is 26.14% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Cash from Operations of -$232.3 million as of FY2024, which was down 26.14% from -$184.2 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's Cash from Operations' 5-year high stood at -$29.8 million during FY2020, with a 5-year trough of -$232.3 million in FY2024.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Cash from Operations value was -$184.2 million (recorded in 2023), while the average stood at -$170.1 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first rose by 17.41% in 2020, then plummeted by 96.26% in 2023.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Cash from Operations stood at -$29.8 million in 2020, then crashed by 83.29% to -$54.6 million in 2021, then crashed by 71.92% to -$93.8 million in 2022, then tumbled by 96.26% to -$184.2 million in 2023, then dropped by 26.14% to -$232.3 million in 2024.